5.55

2.17% -0.03

After Hours: 5.40 -0.15 -2.70%

Cns Pharmaceuticals Inc (CNSP)

Overview News Price History Financials Discussions Forecast Stock Split

Cns Pharmaceuticals Inc stock is traded at $5.55, with a volume of 3,537. It is down -2.17% in the last 24 hours and up +7.14% over the past month. CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.

Previous Close:

$5.52

Open:

$5.51

24h Volume:

3,537

Relative Volume:

0.11

Market Cap:

$8.11M

Revenue:

Net Income/Loss:

$-16.49M

P/E Ratio:

-0.1873

EPS:

-29.6295

Net Cash Flow:

$-15.24M

1W Performance:

+5.26%

1M Performance:

+7.14%

6M Performance:

+65.64%

1Y Performance:

+6.09%

1-Day Range:

$5.40

$5.81

1-Week Range:

$4.85

$5.81

52-Week Range:

$1.90

$10.59

Cns Pharmaceuticals Inc Stock (CNSP) Company Profile

Name

Cns Pharmaceuticals Inc

Sector

Healthcare (1089)

Industry

Biotechnology (604)

Phone

1-800-946-9185

Address

2100 WEST LOOP SOUTH, HOUSTON

Employee

Twitter

Next Earnings Date

2026-08-13

Latest SEC Filings

CNSP's Discussions on Twitter

Compare CNSP vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CNSP Cns Pharmaceuticals Inc	5.55	8.07M	0	-16.49M	-15.24M	-29.63
VRTX Vertex Pharmaceuticals Inc	515.57	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	805.86	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	986.80	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	211.94	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.66	39.31B	5.76B	514.49M	1.10B	4.4813

Cns Pharmaceuticals Inc Stock (CNSP) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-28-20	Downgrade	Ladenburg Thalmann	Buy → Neutral
Aug-24-20	Initiated	Ladenburg Thalmann	Buy

Cns Pharmaceuticals Inc Stock (CNSP) Latest News

05:32 AM

Central Nervous System (CNS) Lymphoma Market Outlook Signals Expansion To $2.08 Billion Through 2030 - openPR.com

05:32 AM

Aug 14, 2026

Ikarian Capital (CNSP) discloses 9.9% beneficial ownership in CNS Pharmaceuticals - Stock Titan

Aug 14, 2026

Aug 12, 2026

CNS Pharmaceuticals Releases Q2 2026 Financial Results - AlphaStreet

Aug 12, 2026

CNS PHARMACEUTICALS ($CNSP) Releases Q2 2026 Earnings - Moomoo

Aug 12, 2026

CNS Pharmaceuticals Q2 net loss widens, cash rises after financing - TradingView

Aug 12, 2026

CNSP: Accelerated transformation and strong cash position support pipeline expansion and strategic growth - TradingView

Aug 12, 2026

CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic Transformation - accessnewswire.com

Aug 12, 2026

CNS Pharmaceuticals, Inc. Q2 2026: Net loss $2.59M, EPS $(0.38) — 10-Q Summary - TradingView

Aug 12, 2026

CNS Pharmaceuticals Expects to In-License or Acquire Assets by Year-End 2026 - Stock Titan

Aug 12, 2026

Aug 10, 2026